FDA Asks Wyeth For Additional Safety Study To Support Pristiq Vasomotor Claim
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency’s request will delay potential vasomotor symptoms launch by at least a year, but does not affect FDA review of the Effexor follow-on for major depressive disorder, Chief Medical Officer Stiles says.